NASDAQ:AVIR - Atea Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $69.33
  • Forecasted Upside: 54.28 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$44.94
▼ -1.07 (-2.33%)
1 month | 3 months | 12 months
Get New Atea Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVIR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVIR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$69.33
▲ +54.28% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Atea Pharmaceuticals in the last 3 months. The average price target is $69.33, with a high forecast of $82.00 and a low forecast of $60.00. The average price target represents a 54.28% upside from the last price of $44.94.
Buy
The current consensus among 4 investment analysts is to buy stock in Atea Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2021Morgan StanleyBoost Price TargetOverweight$49.00 ➝ $82.00Medium
i
4/6/2021Morgan StanleyBoost Price TargetOverweight$49.00 ➝ $82.00High
i
1/29/2021JPMorgan Chase & Co.Boost Price TargetOverweight$45.00 ➝ $66.00High
i
11/24/2020Evercore ISIInitiated CoverageOutperformHigh
i
11/24/2020Morgan StanleyInitiated CoverageOverweight$49.00Low
i
11/24/2020JPMorgan Chase & Co.Initiated CoverageOverweight$45.00Low
i
11/24/2020William BlairInitiated CoverageOutperform$60.00Medium
i
Rating by T. Lugo at William Blair
(Data available from 4/19/2016 forward)
Atea Pharmaceuticals logo
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. It also develops AT-787 which is under phase 2 clinical for the treatment of hepatitis C virus; AT-752 which is under phase 2 clinical trial for the treatment of dengue; and AT-889, AT-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. The company was incorporated in 2012 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $44.94
$43.72
$46.95

50 Day Range

MA: $64.67
$46.01
$81.29

52 Week Range

Now: $44.94
$24.15
$94.17

Volume

434,400 shs

Average Volume

320,751 shs

Market Capitalization

$3.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Atea Pharmaceuticals?

The following sell-side analysts have issued research reports on Atea Pharmaceuticals in the last year: Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, William Blair, and Zacks Investment Research.
View the latest analyst ratings for AVIR.

What is the current price target for Atea Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Atea Pharmaceuticals in the last year. Their average twelve-month price target is $69.33, suggesting a possible upside of 54.3%. Morgan Stanley has the highest price target set, predicting AVIR will reach $82.00 in the next twelve months. William Blair has the lowest price target set, forecasting a price of $60.00 for Atea Pharmaceuticals in the next year.
View the latest price targets for AVIR.

What is the current consensus analyst rating for Atea Pharmaceuticals?

Atea Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVIR will outperform the market and that investors should add to their positions of Atea Pharmaceuticals.
View the latest ratings for AVIR.

What other companies compete with Atea Pharmaceuticals?

How do I contact Atea Pharmaceuticals' investor relations team?

The company's listed phone number is 857 284 8891 and its investor relations email address is [email protected] The official website for Atea Pharmaceuticals is www.ateapharma.com.